Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs?
نویسندگان
چکیده
منابع مشابه
Cardiovascular safety evaluation in the development of new drugs for diabetes mellitus.
2705 T he burden of type 2 diabetes mellitus across the United States continues to increase. Today, ≈25.8 million Americans are affected by type 2 diabetes mellitus, and its incidence in the Medicare age group exceeds 25%. The number of newly diagnosed subjects with type 2 diabetes mel-litus aged >20 years approximated 1.9 million in the year 2010 alone, and the direct and indirect costs of man...
متن کاملDiabetes Drugs and Cardiovascular Safety
Diabetes is a well-known risk factor of cardiovascular morbidity and mortality, and the beneficial effect of improved glycemic control on cardiovascular complications has been well established. However, the rosiglitazone experience aroused awareness of potential cardiovascular risk associated with diabetes drugs and prompted the U.S. Food and Drug Administration to issue new guidelines about ca...
متن کاملDiabetes mellitus: new drugs for a new epidemic.
The prevalence of diabetes mellitus (DM) is increasing rapidly in the 21st century as a result of obesity, an ageing population, lack of exercise, and increased migration of susceptible patients. This costly and chronic disease has been likened recently to the 'Black Death' of the 14th century. Type 2 DM is the more common form and the primary aim of management is to delay the micro- and macrov...
متن کاملNew drugs for the treatment of diabetes mellitus: part I: Thiazolidinediones and their evolving cardiovascular implications.
The cardiovascular disease (CVD) risk associated with diabetes mellitus (DM) has become increasingly evident, accounting for 80% of deaths among patients with this disease1 and making CVD risk modification a key therapeutic objective in diabetic patients. Indeed, in some clinical contexts, DM has been elevated to a coronary heart disease risk equivalent for risk reduction strategies.1–4 The rap...
متن کاملDapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
Sodium-glucose co-transporter 2 inhibitors (SGLT2is) such as dapagliflozin, canagliflozin, and empagliflozin, are a promising new therapy in the treatment of type 2 diabetes mellitus (T2DM). SGLT2is can effectively reduce hyperglycemia thus improving glycemic control and they offer some beneficial effects on the cardiovascular (CV) system which can benefit patients with heart failure in additio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2019
ISSN: 0009-7322,1524-4539
DOI: 10.1161/circulationaha.118.038771